917P - The role of radiation therapy in DLBCL treatment in a single institution study

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Haematologic Malignancies
Presenter Iryna Kryachok
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors I. Kryachok1, O. Aleksyk2, K. Filonenko1, Z. Fedorenko3, I. Tytorenko4, A.V. Martynchyk2, I. Stepanishyna5, L. Koutsenko3
  • 1Oncohematology, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA
  • 2Oncology/hematology, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA
  • 3Department Of Cancer Epidemiology And National Cancer Registry, National Cancer Institute, Kiev/UA
  • 4Oncohematology, National Cancer Institute of the MPH Ukraine, Kiev/UA
  • 5Department Of Chemotherapy Of Hemablastoses, National Cancer Institute, 03022 - Kyiv/UA

Abstract

Background

The role of radiation therapy in patients with diffuse large B-cell lymphoma (DLBCL) is not clearly defined, especially in patients with advanced stages of the disease.

Methods

We have analyzed the data of 364 patients with DLBCL, stage I-IV, 176 males and 186 females, age 18-84 years old, treated in our department from 2010 to 2016. We have analyzed overall survival (OS) in patients treated with or without radiation therapy depending on the stage (early vs. advanced) and presence of rituximab in the chemotherapy (R-CHOP vs. CHOEP).

Results

Early stages had 199 patients, advanced stages – 165 patients. Chemotherapy with rituximab received 66 patients, without rituximab – 21 patients. Chemoradiotherapy with rituximab received 206 patients, without rituximab – 71 patients. 5-year OS in the group of chemotherapy with rituximab was 74%, chemotherapy without rituximab – 61%, chemoradiotherapy with rituximab – 81%, chemoradiotherapy without rituximab – 82%. The significant difference in OS rates was revealed only between the groups of chemoradiotherapy with vs. without rituximab (p = 0.026) and chemotherapy with rituximab vs. chemoradiotherapy with rituximab (p = 0.01). In the early stages group 5-year OS was 77% in patients treated with chemotherapy vs. 84% in patients treated with chemoradiotherapy, p = 0.24. In the late stages group 5-year OS was 64% in patients treated with chemotherapy vs. 78% in patients treated with chemoradiotherapy, p = 0.26.

Conclusions

Significantly higher 5-year OS was sen in the group of patients with DLBCL treated with chemotherapy with rituximab compared with those who were treated without rituximab. Significantly higher 5-year OS was seen in the group of patients treated with chemoradiotherapy with rituximab compared with those treated with chemotherapy with rituximab. There were no significant differences between other groups of patients. Radiotherapy did not influence OS rate depending on the stage of the disease.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Ministry of Health of Ukraine

Disclosure

All authors have declared no conflicts of interest.